Cargando…
Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most common cancer death reasons. Anti-tumor necrosis factor-alpha (TNF-α) antibodies have shown promising effects in PDAC pre-clinical models. However, the prognostic values of TNF-α, underlying mechanisms by which anti-TNF-α treatme...
Autores principales: | Zhao, Xianda, Fan, Wei, Xu, Zhigao, Chen, Honglei, He, Yuyu, Yang, Gui, Yang, Gang, Hu, Hanning, Tang, Shihui, Wang, Ping, Zhang, Zheng, Xu, Peipei, Yu, Mingxia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348380/ https://www.ncbi.nlm.nih.gov/pubmed/27835602 http://dx.doi.org/10.18632/oncotarget.13212 |
Ejemplares similares
-
Desmoplasia and Chemoresistance in Pancreatic Cancer
por: Schober, Marvin, et al.
Publicado: (2014) -
Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
por: Ramani, Vishnu C., et al.
Publicado: (2015) -
Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential
por: Cannon, Andrew, et al.
Publicado: (2018) -
Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia
por: Creeden, Justin F., et al.
Publicado: (2020) -
Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials
por: Xu, Zhigao, et al.
Publicado: (2017)